Member Info for crumbs

possibly the US arm of SCIB1 will be canned? and a UK cheaper one took on?

The proactive presentation is nothing new... they have done loads of presentations what scancell have on offer is amazing it just seems to be constantly stuck .... and CH and JC have only brought shareholders a constantly falling sp to go with it.. so for those 2 in my report I'm going to say -could do better! ....We could surely do with being a part of a Genentech just to get the techs proven!

Well yeah :) so long as they don't come and ask us to pay for our pressies ...

Yes nothing changed its just a bit like you have an exciting build up for Christmas and the coming gifts only to be told its been moved from December to April...even GC results moved to a later date from the original ... so maybe a nice little BioNtech deal to be going on with? or something! At least give the new platform a name and get it presented properly with some unrealistic timelines attached to it lol

Ahh... ok well at that must help the case to the FDA.?.. and yeah I'm going to buy more but it is another case of another ball getting kicked further into the long grass... hopefully everything will be green for go in 2019 and this will have been a great buying time...

They RNS it because they are going to have to talk about it at AGM lol they can't hide it any longer... so better they get it out now... does not seem to be any more updates coming... let us see how the market reacts but really for us LTH its nothing new and nothing fatal ... I'll be sucking up some sub 10p getting shares cheaper than JC got his as one consolation oh how he and his buddies deserve their wages from raised funds...

Yeah, nothing coming on the new nano delivery either... could that hold up SCIB2 combo trial... yes!

Isn't the new Ichor already approved for a trial over there?... I'm sure it will all get sorted but it means SCIB1 combo trial gets pushed back once again meanwhile .... hundreds of others CI combo trials are running already... does seem to me scancell need a big buddy... we really do need a big player partner

lol seems you were patiently waiting for that one..... doubt you'll get your apology:)
One thing we should have all learnt here by now is that timelines are meaningless they are future hopes with no definite beginnings to be fair with this one it seems to be more down to a third party (Ichor) than scancell but still JC is over there and Ichor are his San Diego neighbours.... pull yer fingers out

I suppose they had to get that block out before AGM.... but it is like a never-ending story we knew about Ichor hold up months ago ! Were led to believe all was in hand but the silence since pretty much can now be explained lol... hopefully SCIB2 trials pieces are coming together more smoothly though nothing about nano delivery still... be a great share this in 2030 :)

More delays.... oh well

In theory and it remains an in theory at this moment in time... but scancell has the potential tech to eat up most of the immuno market which would make scancell worth as much if not more than any big pharma... Merck is pinning most of its hopes on Keytruda ... but that is a first gen immuno product and the CI science behind it Merck do not own... no pharma has a monopoly on CI on CAR T on TCR or RNA etc etc.... scancell own the patent to moditope... moditope could be an industry all on its own... then there are ImmunoBody and now this new glyco platform... JC has chaired scancell for a few years now and brought no sp value at all the sp is probably 50% less or more than when he was appointed... the science and data has never stopped though and the potential is greater than ever but it will be interesting to hear what he has to say this year ...lets hope he is smiling more than Lindy! :)

GC awards will be announced in January now... Hopefully we will all be more up to date after AGM LD might introduce the new platform etc

I hope we end up bigger than a pizza ....Be nice if our techs end up as well known as pizza is too... Always felt we never got sp recognition of SCIB1 trial success when we all know if it had any trial failure the sp would have collapsed let's hope coming trials react better

things move in decades here not days lol... not sure we are due any near-term news?... hopefully it will be a positive AGM and JC will be disappointed with sp and claim it should be 1000x higher :)... notice there is a new tweet... concerning the glyco platform well done boom... at least here we now have 3 platforms any one of which could make us bigtime and all of them together .... bigger than a Pfizer? ... well if they work - yes

It will pay to pick the right next-gen therapies... one darling of the moment just took a blow:

https://www.marke****ch.com/story/adaptimmunes-stock-tumbles-after-cancer-study-results-prompts-price-target-cut-2018-10-22

Shares of Adaptimmune Therapeutics PLC ADAP, -29.83% slumped 21% in morning trade Monday, after the results from a trial of its cancer treatment prompted Raymond James to slash its price target. The biopharmaceutical company said over the weekend that it was encouraged by the safety data from ongoing studies of SPEAR T-cells, but said no patients were treated in a Cohort 2 "triple tumour" study because the Safety Review Committee recommended an escalated dose. Raymond James analyst Reni Benjamin cut his target to $16 from $20, as the true efficacy of the product may only be determined at the higher, 5-billion-cell dose level. "Although still early, we believe higher doses will likely need to be evaluated with a larger population," Benjamin wrote in a note to clients. "We are decreasing our probability of success from 35% to 25% as we await a stronger correlation between dose, persistence, and clinical response." The stock has slumped 19% over the past three months but was still up 27% year to date, while the S&P 500 SPX, -0.43% has slipped 1.2% the past three months and has gained 3.6% this year.

Merck and BMS are battling it out to dominate the Immuno market with their CI's can only be good for us seeing as they are first gen therapies and need combo help.... that every other major pharma and big biotech is in the fray too and that next gen treatments will come to dominate puts us in a nice position if our trials get on ASAP and all go as well as they could.
https://www.businessinsider.ie/drugmakers-fighting-for-immunotherapy-share-2018-10

It means modi1 ought to be effective in the 90% 95% and 100% of patients in those cancers where they have the Vimentin and enolase expression...I expect only the patients that do express will be enrolled for trial... it shows most patients ought to be suitable which is great... what we will not know till trial is how many will indeed benefit... 100%? well it works that well in humanised mice and on just one injection!...but we expect there will be other factors affecting the outcome such as the state of the patients immune system and general health which due to the late stage of their disease will be compromised... this is where the BioNtech tie-up comes in... it is possible modi1 will become an off the shelf highly effective and safe mono treatment in a majority and in those it does not work in the BioNtech modi approach where souped-up T Cells are grown outside the patient and reinfused could cover those who's immune systems need that approach... we can only wait and see but the science is compelling and the animal model data is next to no other... you cannot improve on 100% after all...

Think maybe your confusing the 100% humanised mouse survival with the % of potentially suitable patients for modi1 treatment in certain cancer types... the mice are given a specific cancer if I'm right I think it is melanoma and they survive 100% even with maximum ethically allowable tumour load... the tumours vanish the mice live... and even when the cancer is reintroduced the mice show an immune memory effect and survive.

Many working in the field do not grasp the science of immunology.. when you consider some of the techs that pharma and investor millions are wasted on and what pharma throw into combos together with no more scientific rationale beyond we have this and this lets try em together and see... which is why backing LD is smart and you only need to look at team blueprint to understand that the cutting edge immunologists of our age get where she is coming from... I think with BioNtech and Genentech we are in good company and may even become ..... one company one day.